☆ 4.7 Article

A 3-Year Survival Update from a Phase 2 Study of Paclitaxel Plus Cisplatin and 5-Fuorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial

ANNALS OF SURGICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial

Zhiqiang Wang et al.

Summary: The combination of paclitaxel with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery shows promising safety and efficacy for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC) patients, with significantly better median overall survival in the surgery group compared to the chemoradiotherapy and chemotherapy alone groups. Further exploration of more effective induction chemotherapy regimens is needed to improve R0 resection rates.

ESOPHAGUS (2022)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

Chengqiang Li et al.

Summary: This study investigated the safety and efficacy of preoperative pembrolizumab combined with chemoradiotherapy in resectable oesophageal squamous cell carcinoma patients. The results showed that this treatment was safe and induced a pathological complete response in 55.6% of the tumors.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)

Jianfei Shen et al.

Summary: The study demonstrates that pCR after nCRT is an important prognostic indicator of OS and DFS in patients with ESCC. Additionally, lymph-node status plays a significant role in the prognostic evaluation of esophageal cancer patients.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Meeting Abstract Oncology

Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

L. Shen et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

Tomoya Yokota et al.

ANNALS OF SURGICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma

Takeshi Suzuki et al.

ANNALS OF SURGICAL ONCOLOGY (2020)

添加到收藏夹

Article Biology

Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease

Satoshi Ishikura et al.

JOURNAL OF RADIATION RESEARCH (2020)

添加到收藏夹

Article Oncology

Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

Manish A. Shah et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Epidemiology of Esophageal Squamous Cell Carcinoma

Christian C. Abnet et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

Hong Yang et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A)

Motoo Nomura et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Lordick et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer

Tomoya Yokota et al.

BRITISH JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

AC Berger et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.